Nektar Therapeutics

NasdaqCM:NKTR Stock Report

Market Cap: US$193.7m

Nektar Therapeutics Management

Management criteria checks 3/4

Nektar Therapeutics' CEO is Howard Robin, appointed in Jan 2007, has a tenure of 17.83 years. total yearly compensation is $3.14M, comprised of 34.6% salary and 65.4% bonuses, including company stock and options. directly owns 0.37% of the company’s shares, worth $707.46K. The average tenure of the management team and the board of directors is 5.8 years and 16.3 years respectively.

Key information

Howard Robin

Chief executive officer

US$3.1m

Total compensation

CEO salary percentage34.6%
CEO tenure17.8yrs
CEO ownership0.4%
Management average tenure5.8yrs
Board average tenure16.3yrs

Recent management updates

Recent updates

Investor Optimism Abounds Nektar Therapeutics (NASDAQ:NKTR) But Growth Is Lacking

Oct 18
Investor Optimism Abounds Nektar Therapeutics (NASDAQ:NKTR) But Growth Is Lacking

Some Nektar Therapeutics (NASDAQ:NKTR) Shareholders Look For Exit As Shares Take 35% Pounding

Jun 19
Some Nektar Therapeutics (NASDAQ:NKTR) Shareholders Look For Exit As Shares Take 35% Pounding

There's No Escaping Nektar Therapeutics' (NASDAQ:NKTR) Muted Revenues Despite A 44% Share Price Rise

Feb 15
There's No Escaping Nektar Therapeutics' (NASDAQ:NKTR) Muted Revenues Despite A 44% Share Price Rise

Nektar Therapeutics' (NASDAQ:NKTR) Business And Shares Still Trailing The Industry

Dec 31
Nektar Therapeutics' (NASDAQ:NKTR) Business And Shares Still Trailing The Industry

Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Invest In Growth?

Nov 06
Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Invest In Growth?

Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Invest In Growth?

Apr 24
Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Invest In Growth?

Here's Why Nektar Therapeutics (NASDAQ:NKTR) Must Use Its Cash Wisely

Jan 24
Here's Why Nektar Therapeutics (NASDAQ:NKTR) Must Use Its Cash Wisely

Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Deliver On Growth Plans?

Aug 19
Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Deliver On Growth Plans?

Nektar: Time To Abandon Ship

Jul 17

Nektar promotes internal executive to CFO role

Jul 01

We Think Nektar Therapeutics (NASDAQ:NKTR) Needs To Drive Business Growth Carefully

May 11
We Think Nektar Therapeutics (NASDAQ:NKTR) Needs To Drive Business Growth Carefully

After A High-Profile Failure In Melanoma, Nektar Therapeutics' Value Shifts To Its Early-Stage Pipeline

Apr 04

CEO Compensation Analysis

How has Howard Robin's remuneration changed compared to Nektar Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$168m

Jun 30 2024n/an/a

-US$177m

Mar 31 2024n/an/a

-US$176m

Dec 31 2023US$3mUS$1m

-US$276m

Sep 30 2023n/an/a

-US$294m

Jun 30 2023n/an/a

-US$307m

Mar 31 2023n/an/a

-US$415m

Dec 31 2022US$11mUS$1m

-US$368m

Sep 30 2022n/an/a

-US$454m

Jun 30 2022n/an/a

-US$525m

Mar 31 2022n/an/a

-US$491m

Dec 31 2021US$11mUS$1m

-US$524m

Sep 30 2021n/an/a

-US$495m

Jun 30 2021n/an/a

-US$474m

Mar 31 2021n/an/a

-US$429m

Dec 31 2020US$11mUS$1m

-US$444m

Sep 30 2020n/an/a

-US$439m

Jun 30 2020n/an/a

-US$429m

Mar 31 2020n/an/a

-US$460m

Dec 31 2019US$10mUS$1m

-US$441m

Sep 30 2019n/an/a

-US$427m

Jun 30 2019n/an/a

-US$424m

Mar 31 2019n/an/a

US$657m

Dec 31 2018US$13mUS$969k

US$681m

Sep 30 2018n/an/a

US$746m

Jun 30 2018n/an/a

US$903m

Mar 31 2018n/an/a

-US$129m

Dec 31 2017US$18mUS$941k

-US$97m

Compensation vs Market: Howard's total compensation ($USD3.14M) is above average for companies of similar size in the US market ($USD1.46M).

Compensation vs Earnings: Howard's compensation has been consistent with company performance over the past year.

CEO

Howard Robin (71 yo)

17.8yrs

Tenure

US$3,135,576

Compensation

Mr. Howard W. Robin has been the Chief Executive Officer and the President of Prime Holdings & Investments Inc. since July 2001. Mr. Robin has been the Chief Executive Officer and President of Nektar Thera...

Leadership Team

NamePositionTenureCompensationOwnership
Howard Robin
CEO, President & Director17.8yrsUS$3.14m0.37%
$ 707.5k
Sandra Gardiner
Chief Financial Officer1.6yrsUS$376.30kno data
Mark Wilson
Senior VP8.3yrsUS$1.10m0.12%
$ 229.8k
Jonathan Zalevsky
Chief Research & Development Officer5.1yrsUS$1.77m0.13%
$ 255.2k
Vivian Wu
Director of Investor Relations & Corporate Affairsno datano datano data
Robert Bacci
Senior Vice President of Human Resources & Facilities Operations2.9yrsno datano data
Jennifer Ruddock
Chief Business Officer5.8yrsno datano data
Mary Tagliaferri
Chief Medical Officer7yrsno datano data

5.8yrs

Average Tenure

58yo

Average Age

Experienced Management: NKTR's management team is seasoned and experienced (5.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Howard Robin
CEO, President & Director17.8yrsUS$3.14m0.37%
$ 707.5k
Robert Chess
Independent Chairman of the Board32.5yrsUS$176.22k0.14%
$ 274.7k
R. Greer
Independent Director14.8yrsUS$170.22k0.16%
$ 318.8k
Roy Whitfield
Lead Independent Director24.3yrsUS$170.22k0.16%
$ 302.1k
Jeffrey Ajer
Independent Director7.2yrsUS$134.22k0.019%
$ 35.9k
Diana Brainard
Independent Director3yrsUS$112.72k0.012%
$ 23.6k

16.3yrs

Average Tenure

66.5yo

Average Age

Experienced Board: NKTR's board of directors are seasoned and experienced ( 16.3 years average tenure).